9 արդյունքներ
BACKGROUND OF THE INVENTION
Certain phenyl-alkanoic acids are known from the literature and some of them are said to possess valuable pharmacological activities, for example, an analgesic, anti-inflammatory or anti-pyretic action, whereas others are used clinically, for example, in the treatment of
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention encompasses the clinical uses of zinc complexes of natural amino acids, such as those natural amino acids with basic side chains, for example L-arginine, lysine, ornithine, and histidine, and other alpha amino acids of natural
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
FIELD OF THE INVENTION
This invention relates to the field of atherosclerosis. In particular, this invention pertains to the identification of a class of peptides that are orally administrable and that ameliorate one or more symptoms of atherosclerosis.
BACKGROUND OF THE INVENTION
Cardiovascular
FIELD OF THE INVENTION
The present invention relates to skin care cosmetic compositions and methods. In particular, the present invention relates to novel cosmetic compositions and methods for retarding hair growth.
BACKGROUND OF THE INVENTION
For years, companies have marketed products for either